Australia GM1 Gangliosidosis Market Size & Outlook, 2026-2034
Australia GM1 Gangliosidosis Market Insights
- According to Reed Intelligence analysis, the Australia GM1 Gangliosidosis Market size was USD 2.27 Million in 2025 and is projected to reach USD 9.16 Million by 2034.
- The Australia market is projected to grow at a CAGR of 16.82% between 2026 and 2034.
- By segment, Gene Therapy emerged as the largest By Therapy Type in terms of market size in 2025.
- Enzyme Replacement Therapy is anticipated to remain the most attractive By Therapy Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, Australia held 1.23% of the global GM1 Gangliosidosis Market size.
- By 2034, United States is anticipated to capture the largest share of the global GM1 Gangliosidosis Market.
- In Asia Pacific, China is expected to lead the regional GM1 Gangliosidosis Market size by 2034.
- Australia will remain the fastest-growing market in Asia Pacific, reaching USD 9.2 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 2.27 Million |
| Market Size In 2034 | USD 9.16 Million |
| Largest segment | Gene Therapy |
| Units | Revenue in USD Million |
| CAGR | 16.82% (2026-2034) |
| Segmnetation Covered | |
| By Therapy Type |
|
| By Disease Type |
|
| By Treatment Modality |
|
| By End-Use |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Australia GM1 Gangliosidosis Market By Therapy Type 2026-2034 (USD Million)
| By Therapy Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Therapy | XX.x | XX.x | XX.x | 1.19 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme Replacement Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Substrate Reduction Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia GM1 Gangliosidosis Market By Disease Type 2026-2034 (USD Million)
| By Disease Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type 1 (Infantile) | XX.x | XX.x | XX.x | 1.04 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Type 2 (Juvenile) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Type 3 (Adult/Chronic) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia GM1 Gangliosidosis Market By Treatment Modality 2026-2034 (USD Million)
| By Treatment Modality | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacological Treatment | XX.x | XX.x | XX.x | 1.21 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gene Editing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Supportive Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia GM1 Gangliosidosis Market By End-Use 2026-2034 (USD Million)
| By End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 1.05 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia GM1 Gangliosidosis Market By Distribution Channel 2026-2034 (USD Million)
| By Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 1.23 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.